Drug Profile
Eptapirone
Alternative Names: F-11440Latest Information Update: 14 Dec 2006
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antidepressants; Anxiolytics; Piperazines; Pyrimidines; Small molecules; Triazines
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 19 Aug 2003 No development reported - Phase-I for Anxiety disorders in France (PO)
- 19 Aug 2003 No development reported - Phase-I for Depression in France (PO)
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance